The treatment of the illness has been revolutionized by the use of the medication as a initial therapy for patients with progressed lung cancer (NSCLC) harboring EGFR alterations.Despite its efficacy, a substantial number of individuals develop resistance to the medication, necessitating the exploration of other therapeutic approaches.A new method that holds great hope is the combination of the medication with blockage of Jak activity, which is such a strategy.This article will delve into the reason for combining blockage of Jak activity with the medication therapy, investigate the potential difficulties, and…
